2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease coursePD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchRetrospective cohort studyProstate-specificProstate cancerImaging findingsCohort studyPatientsPD45CancerRetrospectivelyImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2019
Racial Differences in Health Care Transitions and Hospice Use at the End of Life
Wang SY, Hsu SH, Aldridge MD, Cherlin E, Bradley E. Racial Differences in Health Care Transitions and Hospice Use at the End of Life. Journal Of Palliative Medicine 2019, 22: 619-627. PMID: 30615546, PMCID: PMC6533794, DOI: 10.1089/jpm.2018.0436.Peer-Reviewed Original ResearchConceptsHealth care transitionCare transitionsEnd of lifeHospice enrollmentHospice useLife careEthnic differencesAfrican AmericansRetrospective cohort studyMonths of lifeRace/ethnic groupsPatterns of endHospice disenrollmentCohort studyNonwhite patientsWhite patientsHospice enrolleesRacial/Ethnic DifferencesMedicare beneficiariesHospice usersDisenrollment ratesMean numberRacial differencesCareAsian Americans
2016
Transitions Between Healthcare Settings of Hospice Enrollees at the End of Life
Wang SY, Aldridge MD, Gross CP, Canavan M, Cherlin E, Johnson-Hurzeler R, Bradley E. Transitions Between Healthcare Settings of Hospice Enrollees at the End of Life. Journal Of The American Geriatrics Society 2016, 64: 314-322. PMID: 26889841, PMCID: PMC4762182, DOI: 10.1111/jgs.13939.Peer-Reviewed Original ResearchConceptsMonths of lifeSkilled nursing facilitiesHospice enrollmentHealthcare settingsNursing facilitiesHospice usersHospital-based palliative careRetrospective cohort studyHome health agenciesEnd of lifeCohort studyPalliative careCare transitionsHospice enrolleesHealthcare transitionHigher oddsClaims dataHospice decedentsMedicare beneficiariesHospice programsHospiceHealth agenciesCareNotable proportionDecedents